Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients [0.03%]
CAR-T细胞治疗后的二次原发性恶性肿瘤：5517例淋巴瘤和多发性骨髓瘤患者的系统评价和.meta.分析
Tobias Tix,Mohammad Alhomoud,Roni Shouval et al.
Tobias Tix et al.
Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long-term adverse events, including second primary malignancies (SPM) that impact mo...
The Intrauterine Device: How to Deploy This Strategy in the Molecular World? [0.03%]
宫内节育器：如何在分子世界中部署这一策略？
Paul Johannet,Claire F Friedman
Paul Johannet
Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine ...
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial [0.03%]
来自ETOP-BOOSTER随机Ⅱ期试验的奥希替尼单药或联合贝伐珠单抗治疗患者的ctDNA变化及耐药机制研究
Ross A Soo,Urania Dafni,Ji-Youn Han et al.
Ross A Soo et al.
Purpose: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistan...
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma [0.03%]
替唑_FIX_酰胺治疗晚期肾细胞癌的FDA批准概述
Jaleh Fallah,Brian L Heiss,Hee-Koung Joeng et al.
Jaleh Fallah et al.
On December 14, 2023, the U.S. FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. The FDA granted ...
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival [0.03%]
黑色素瘤新辅助抗PD-1治疗后肿瘤坏死区域中浸润淋巴细胞与病理缓解和无复发生存率相关
Kevin L Ma,Tara C Mitchell,Meaghan Dougher et al.
Kevin L Ma et al.
Purpose: Neoadjuvant anti-PD-1 therapy in melanoma may increase tumor-infiltrating lymphocytes (TIL), and more TIL are associated with better treatment response. A major pathologic response (MPR) in melanoma after neoadju...
A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies [0.03%]
cinrebafusp阿尔法（HER2/4-1BB双特异性分子）治疗HER2阳性晚期实体瘤患者的首次人体研究
Sarina Piha-Paul,Shane A Olwill,Erika Hamilton et al.
Sarina Piha-Paul et al.
Purpose: 4-1BB (CD137) is a costimulatory immune receptor expressed on activated T cells, activated B cells, natural killer cells and tumor-infiltrating lymphocytes, making it a promising target for cancer immunotherapy. ...
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma [0.03%]
美国食品药品监督管理局批准说明书概要：恩Fortumab Vedotin联合派姆单抗治疗局部晚期或转移性尿路上皮癌
Michael H Brave,William F Maguire,Chana Weinstock et al.
Michael H Brave et al.
On December 15, 2023, the FDA granted traditional approval to enfortumab vedotin-ejfv plus pembrolizumab (EV + Pembro) for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Substantial evidence of effectiveness was...
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies [0.03%]
理解并克服选择性成纤维细胞生长因子受体抑制剂在FGFR2致病恶性肿瘤中的抵抗性
Francesco Facchinetti,Yohann Loriot,Floriane Brayé et al.
Francesco Facchinetti et al.
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies. Exp...
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer [0.03%]
阿特朱单抗、帕妥珠单抗和大剂量赫赛汀治疗HER2阳性乳腺癌脑转移患者的II期研究
Antonio Giordano,Priya U Kumthekar,Qingchun Jin et al.
Antonio Giordano et al.
Purpose: Patients with HER2-positive breast cancer brain metastases have few effective systemic therapy options. In a prior study, pertuzumab with high-dose trastuzumab demonstrated a high clinical benefit rate (CBR) in t...
Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer [0.03%]
膀胱神经内分泌癌的基因组谱和免疫表型分析
Jingyu Zang,Akezhouli Shahatiaili,Mei-Chun Cai et al.
Jingyu Zang et al.
Purpose: Neuroendocrine bladder cancer (NEBC) poses a formidable clinical challenge and attracts keen interests to explore immunotherapy as a viable treatment option. However, a comprehensive immunogenomic landscape has y...